The European Commission's approval of Pyzchiva represents a significant milestone for Sandoz, potentially leading to increased market share in the immunology sector. This approval could positively impact investor sentiment and the stock price in the short term, as it demonstrates Sandoz's ability to expand its portfolio with competitive biosimilar products. The approval also reinforces Sandoz's commitment to improving access to important treatments, which could enhance its reputation and financial performance.